QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022Business Wire • 01/06/23
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in CanadaZacks Investment Research • 12/20/22
Health Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial InfarctionBusiness Wire • 12/19/22
QuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® PlatformBusiness Wire • 12/16/22
QuidelOrtho Announces Separation of Chairman and Chief Executive Officer RolesBusiness Wire • 12/12/22
QuidelOrtho (QDEL) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 12/02/22
3 Medical Products Stocks Navigating Industry Challenges (Revised)Zacks Investment Research • 11/24/22
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel CorporationBusiness Wire • 10/04/22